相关实验视频

Updated: May 24, 2025

Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy

Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy

Published on: May 21, 2014

解蛋白3通过降低阿斯巴酸盐的调节,防止病态心脏缩

Yajun Wang¹, Jiliang Tan¹, Luxiao Li²

¹Laboratory of Molecular Cardiology, CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences (CAS), Shanghai 200031, PR China.

Journal of molecular and cellular cardiology

|March 4, 2025

概括

线粒体解蛋白3 (UCP3) 在心脏缩中减少. 增加UCP3通过降低阿斯巴酸盐水平来缓解这种情况,提供了一个新的治疗点.

科学领域:

心脏病学心脏病学
线粒体生物学线粒体生物学
生物化学生物化学

背景情况:

心脏缩涉及代谢变化,但调节线粒体三糖酸循环中间体的机制尚不清楚.
线粒体解蛋白3 (UCP3) 保护心脏,但其在压力过载引起的缩中的作用尚不清楚.

研究的目的:

研究UCP3在压力过载引起的心脏缩中的作用.
阐明UCP3影响心脏缩的分子机制.

主要方法:

在小鼠中利用横向大动脉收缩 (TAC) 诱导心脏缩.
在体外研究中使用烯 (PE) 刺激的新生小鼠心肌细胞 (NRCMs).
评估了UCP3表达,心脏功能和代谢中间体 (酸盐,GOT2活性).
生成的全球和心脏特异性UCP3淘汰 (UCP3cKO) 和UCP3过度表达 (UCP3cOE) 鼠标模型.

主要成果:

在TAC诱导的高性小鼠心脏和PE刺激的NRCM中,UCP3的下调.
缺乏UCP3会加剧TAC诱导的缩和功能障碍,而UCP3过度表达会改善这种情况.
UCP3调节了阿斯巴酸盐水平和GOT2活性,UCP3缺乏增强了它们,过度表达逆转了这些影响.
亚斯巴甜酸补充剂抵消了PE治疗的NRCMs中UCP3过度表达所见的过度缩改善.

结论:

在心脏缩时,UCP3的表达减少.
UCP3减轻心脏缩,部分是通过降低增强的阿斯巴酸盐水平.
UCP3代表了心脏缩的潜在治疗标.

关键词:

亚斯巴酸盐是一种在GOT2中,GOT2是GOT2.过度缩过度缩过度缩代谢过程中的代谢.在 UCP3 中,UCP3 是一个 UCP3 系统.

更多相关视频

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

Published on: August 1, 2016

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

相关概念视频

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...